Gemfibrozil: Difference between revisions
No edit summary |
|||
| Line 10: | Line 10: | ||
'''Gemfibrozil''' is the [[International Nonproprietary Name|generic name]] for an oral drug used to lower [[lipid]] levels. It belongs to a group of drugs known as [[fibrates]]. It is most commonly sold as the brand name, '''Lopid'''. | '''Gemfibrozil''' is the [[International Nonproprietary Name|generic name]] for an oral drug used to lower [[lipid]] levels. It belongs to a group of drugs known as [[fibrates]]. It is most commonly sold as the brand name, '''Lopid'''. | ||
==Category== | ==Category== | ||
Cardiovascular Drug,Phenol ethers,Fibrates，Lipid modifying agents | Cardiovascular Drug,Phenol ethers,Fibrates，Lipid modifying agents | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
''' [[Gemfibrozil indications and usage|Indications and Usage]]''' | ''' [[Gemfibrozil indications and usage|Indications and Usage]]''' | ||
'''| [[Gemfibrozil dosage and administration|Dosage and Administration]]''' | '''| [[Gemfibrozil dosage and administration|Dosage and Administration]]''' | ||
'''| [[Gemfibrozil contraindications|Contraindications]]''' | '''| [[Gemfibrozil contraindications|Contraindications]]''' | ||
'''| [[Gemfibrozil warnings and precautions|Warnings and Precautions]]''' | '''| [[Gemfibrozil warnings and precautions|Warnings and Precautions]]''' | ||
| Line 27: | Line 27: | ||
'''| [[Gemfibrozil clinical pharmacology|Clinical Pharmacology]]''' | '''| [[Gemfibrozil clinical pharmacology|Clinical Pharmacology]]''' | ||
'''| [[Gemfibrozil nonclinical toxicology|Nonclinical Toxicology]]''' | '''| [[Gemfibrozil nonclinical toxicology|Nonclinical Toxicology]]''' | ||
'''| [[Gemfibrozil how supplied storage and handling|How Supplied/Storage and Handling]]''' | '''| [[Gemfibrozil how supplied storage and handling|How Supplied/Storage and Handling]]''' | ||
'''| [[Gemfibrozil labels and packages|Labels and Packages]]''' | '''| [[Gemfibrozil labels and packages|Labels and Packages]]''' | ||
| Line 44: | Line 42: | ||
[[Category:Fibrates]] | [[Category:Fibrates]] | ||
[[Category:Phenol ethers]] | [[Category:Phenol ethers]] | ||
[[ | [[Category:Cardiovascular Drug]] | ||
[[Drug]] | [[Category:Drug]] | ||
Revision as of 18:24, 13 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
For patient information about Gemfibrozil, click here.
Synonyms / Brand Names: LOPID®
Overview
Gemfibrozil is the generic name for an oral drug used to lower lipid levels. It belongs to a group of drugs known as fibrates. It is most commonly sold as the brand name, Lopid.
Category
Cardiovascular Drug,Phenol ethers,Fibrates，Lipid modifying agents
FDA Package Insert
Indications and Usage | Dosage and Administration | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | How Supplied/Storage and Handling | Labels and Packages
Mechanism of Action
The mechanism of action of gemfibrozil has not been definitely established. In man, LOPID has been shown to inhibit peripheral lipolysis and to decrease the hepatic extraction of free fatty acids, thus reducing hepatic triglyceride production. LOPID inhibits synthesis and increases clearance of VLDL carrier apolipoprotein B, leading to a decrease in VLDL production.